Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxapram versus placebo in preterm newborns with apnea of prematurity
NL-OMON55273Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doxapram in apnea of prematurity (AOP) and respiratory failure, sponsored by Erasmus MC. Primary endpoints: Death or severe disability at 2 years corrected age and Survival without severe disability at 2 years corrected age. Started Aug 2020; status: recruiting.
02
Drugs
doxapram
03
Conditions
apnea of prematurity (AOP)respiratory failure
Beyond the preview
Go deeper on NL-OMON55273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55273.